Darzalex Faspro™ (daratumumab and hyaluronidase-fihj) – New formulation approval
May 1, 2020 - The FDA announced the approval of Janssen’s Darzalex Faspro (daratumumab and hyaluronidase-fihj), for the treatment of adult patients with multiple myeloma.
Download PDF
